Expertise in
8
conditions

Dr. Mohit Narang

Oncology | Hematology
Maryland Oncology Hematology PA
11886 Healing Way, 
Silver Spring, MD 
 (743.1 mi)
Accepting New Patients
Offers Telehealth
Expertise in
8
conditions
Maryland Oncology Hematology PA
11886 Healing Way, 
Silver Spring, MD 
 (743.1 mi)
OverviewInsuranceLocationsClinical Research

Overview

Mohit Narang is an Oncologist and a Hematologist in Silver Spring, Maryland. Dr. Narang is highly rated in 8 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Paget Disease of the Breast, Thrombocytopenia, Familial Pancreatic Cancer, and Bone Marrow Transplant. Dr. Narang is currently accepting new patients.

His clinical research consists of co-authoring 27 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Specialist in AR
Hospital Affiliations
Johns Hopkins Howard County Medical Center
Languages Spoken
English
Hindi
Punjabi
Urdu
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  UnitedHealthcare

Locations

MARYLAND ONCOLOGY HEMATOLOGY PA
11886 Healing Way, Silver Spring, MD 20904
Other Locations
MARYLAND ONCOLOGY HEMATOLOGY PA
7350 Van Dusen Rd, Suite 370, Laurel, MD 20707
MARYLAND ONCOLOGY HEMATOLOGY PA
10710 Charter Dr, Suite G020, Columbia, MD 21044

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase II Trial of Daratumumab, Lenalidomide and Dexamethasone (DRd) in Combination With Selinexor for Patients With Newly Diagnosed Multiple Myeloma
A Phase II Trial of Daratumumab, Lenalidomide and Dexamethasone (DRd) in Combination With Selinexor for Patients With Newly Diagnosed Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2025
Intervention Type: Drug
Study Drugs: Selinexor, Dexamethasone Oral, Daratumumab, Lenalidomide
Study Phase: Phase 2
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 31, 2024
Intervention Type: Drug, Device
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy
A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy
Enrollment Status: Active_not_recruiting
Publish Date: April 30, 2024
Intervention Type: Biological, Drug
Study Drugs: Tomivosertib, Pembrolizumab
Study Phase: Phase 2
Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy (FORTE)
Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy (FORTE)
Enrollment Status: Terminated
Publish Date: March 15, 2024
Intervention Type: Drug
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
Enrollment Status: Completed
Publish Date: October 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

27 Total Publications

Characteristics and Treatment Patterns of Long-surviving Patients With Multiple Myeloma: Over 13 Years of Follow-up in the ConnectⓇ MM Registry.
Characteristics and Treatment Patterns of Long-surviving Patients With Multiple Myeloma: Over 13 Years of Follow-up in the ConnectⓇ MM Registry.
Journal: Clinical lymphoma, myeloma & leukemia
Published: July 08, 2024
Similar Doctors
Expertise in
19
conditions
Dr. Bruce D. Cheson
Hematology | Hematology Oncology | Oncology
Expertise in
19
conditions
Dr. Bruce D. Cheson
Hematology | Hematology Oncology | Oncology

American Oncology Partners PA

106 Irving St Nw, Suite 4100, 
Washington, DC 
 (8.8 mi)
202-726-0941
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Bruce Cheson is a Hematologist and a Hematologist Oncology provider in Washington, Washington, D.c.. Dr. Cheson is highly rated in 19 conditions, according to our data. His top areas of expertise are Follicular Lymphoma, Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin Lymphoma, and Bone Marrow Transplant. Dr. Cheson is currently accepting new patients.

Expertise in
28
conditions
Dr. Robert A. Brodsky
Hematology | Oncology
Expertise in
28
conditions
Dr. Robert A. Brodsky
Hematology | Oncology

Johns Hopkins University

600 N Wolfe St, Blalock 266, 
Baltimore, MD 
 (26.0 mi)
410-502-4340
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Robert Brodsky is a Hematologist and an Oncologist in Baltimore, Maryland. Dr. Brodsky is highly rated in 28 conditions, according to our data. His top areas of expertise are Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Cold Hemoglobinuria, Anemia, Bone Marrow Transplant, and Splenectomy. Dr. Brodsky is currently accepting new patients.

Expertise in
25
conditions
Dr. Nina D. Wagner-Johnston
Oncology | Hematology
Expertise in
25
conditions
Dr. Nina D. Wagner-Johnston
Oncology | Hematology

Johns Hopkins University

8600 Old Georgetown Rd, 
Bethesda, MD 
 (9.0 mi)
301-896-3100
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Nina Wagner-Johnston is an Oncologist and a Hematologist in Bethesda, Maryland. Dr. Wagner-Johnston is highly rated in 25 conditions, according to our data. Her top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Wagner-Johnston is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile